DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Factor IX Deficiency Treatment Market 2017-2021" report to their offering.
The global factor IX deficiency treatment market to grow at a CAGR of 5.12% during the period 2017-2021.
The report, Global Factor IX Deficiency Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
According to the report, one driver in the market is shifting toward half-life drugs. Half-life is the reduction of time required for a drug by one-half to get concentrated into the body. The introduction of half-life drugs is a significant improvement in the field of hemophilia B. The less frequent dosing means potentially fewer infusion reactions and lesser opportunities to produce inhibitors, which ultimately leads to increased patient adherence. Thus, it has been observed that the increasing focus on launching drugs with extended half-life has been enabling to increase the adoption rates.
- CSL Behring
- Novo Nordisk
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by disease type
PART 09: Market segmentation by type of therapy
PART 10: Market segmentation by type of disease management
PART 11: Geographical segmentation
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
PART 18: Key vendor analysis
For more information about this report visit http://www.researchandmarkets.com/research/jj5t54/global_factor_ix